Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer’s disease, in murine biological matrices. This method addresses the challenges...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2537118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850072916429897728 |
|---|---|
| author | Emma H. Doud Kasi Hansen Kathryn A. Haynes Kierra Eldridge Jaison Arrivalagan Nitin Charbe Lais Da Silva Sara K. Quinney Amber L. Mosley Stacey J. Sukoff Rizzo Paul R. Territo |
| author_facet | Emma H. Doud Kasi Hansen Kathryn A. Haynes Kierra Eldridge Jaison Arrivalagan Nitin Charbe Lais Da Silva Sara K. Quinney Amber L. Mosley Stacey J. Sukoff Rizzo Paul R. Territo |
| author_sort | Emma H. Doud |
| collection | DOAJ |
| description | A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer’s disease, in murine biological matrices. This method addresses the challenges of quantifying biotherapeutics in multiple tissue types within preclinical animal models with complex genetic backgrounds, where traditional enzyme-linked immunosorbent assay (ELISA) methods may suffer from interference and limited sensitivity. The assay uses parallel reaction monitoring on a Lumos Tribrid Orbitrap mass spectrometer, coupled with an Evosep LC system, and AssayMap Bravo-based automated sample processing. Key features include protein A enrichment for improved sensitivity, optimized peptide selection based on sequence uniqueness and ionization response, and incorporation of stable isotope-labeled peptides for accurate quantification. Assay performance was evaluated for selectivity, repeatability, and stability. The fit-for-purpose assay was successfully applied to quantify chAdu in both mouse cortex and plasma samples obtained from a pilot pharmacokinetic study of a mouse model of amyloid plaque deposition. This targeted mass spectrometry workflow offers a robust and reproducible alternative to ELISA for preclinical biotherapeutic analysis, particularly when dealing with complex biological samples. |
| format | Article |
| id | doaj-art-ba716eac52c847bead1aa48d5fccff85 |
| institution | DOAJ |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-ba716eac52c847bead1aa48d5fccff852025-08-20T02:46:59ZengTaylor & Francis GroupmAbs1942-08621942-08702025-12-0117110.1080/19420862.2025.2537118Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumabEmma H. Doud0Kasi Hansen1Kathryn A. Haynes2Kierra Eldridge3Jaison Arrivalagan4Nitin Charbe5Lais Da Silva6Sara K. Quinney7Amber L. Mosley8Stacey J. Sukoff Rizzo9Paul R. Territo10School of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, Indiana University, Indianapolis, IN, USASchool of Medicine, University of Pittsburgh, Pittsburgh, PA, USASchool of Medicine, Indiana University, Indianapolis, IN, USAA sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer’s disease, in murine biological matrices. This method addresses the challenges of quantifying biotherapeutics in multiple tissue types within preclinical animal models with complex genetic backgrounds, where traditional enzyme-linked immunosorbent assay (ELISA) methods may suffer from interference and limited sensitivity. The assay uses parallel reaction monitoring on a Lumos Tribrid Orbitrap mass spectrometer, coupled with an Evosep LC system, and AssayMap Bravo-based automated sample processing. Key features include protein A enrichment for improved sensitivity, optimized peptide selection based on sequence uniqueness and ionization response, and incorporation of stable isotope-labeled peptides for accurate quantification. Assay performance was evaluated for selectivity, repeatability, and stability. The fit-for-purpose assay was successfully applied to quantify chAdu in both mouse cortex and plasma samples obtained from a pilot pharmacokinetic study of a mouse model of amyloid plaque deposition. This targeted mass spectrometry workflow offers a robust and reproducible alternative to ELISA for preclinical biotherapeutic analysis, particularly when dealing with complex biological samples.https://www.tandfonline.com/doi/10.1080/19420862.2025.2537118Aducanumab5XFADPRMtargeted mass spectrometrybiotherapeuticpharmacokinetics |
| spellingShingle | Emma H. Doud Kasi Hansen Kathryn A. Haynes Kierra Eldridge Jaison Arrivalagan Nitin Charbe Lais Da Silva Sara K. Quinney Amber L. Mosley Stacey J. Sukoff Rizzo Paul R. Territo Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab mAbs Aducanumab 5XFAD PRM targeted mass spectrometry biotherapeutic pharmacokinetics |
| title | Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab |
| title_full | Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab |
| title_fullStr | Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab |
| title_full_unstemmed | Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab |
| title_short | Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab |
| title_sort | analytical development and application of a targeted liquid chromatography tandem mass spectrometry assay for chimeric aducanumab |
| topic | Aducanumab 5XFAD PRM targeted mass spectrometry biotherapeutic pharmacokinetics |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2025.2537118 |
| work_keys_str_mv | AT emmahdoud analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT kasihansen analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT kathrynahaynes analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT kierraeldridge analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT jaisonarrivalagan analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT nitincharbe analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT laisdasilva analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT sarakquinney analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT amberlmosley analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT staceyjsukoffrizzo analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab AT paulrterrito analyticaldevelopmentandapplicationofatargetedliquidchromatographytandemmassspectrometryassayforchimericaducanumab |